Article
Medicine, General & Internal
Sapna P. Patel, Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John R. Hyngstrom, Siwen Hu-Lieskovan, Christopher D. Lao, Leslie A. Fecher, Thach-Giao Truong, Jennifer L. Eisenstein, Sunandana Chandra, Jeffrey A. Sosman, Kari L. Kendra, Richard C. Wu, Craig E. Devoe, Gary B. Deutsch, Aparna Hegde, Maya Khalil, Ankit Mangla, Amy M. Reese, Merrick I. Ross, Andrew S. Poklepovic, Giao Q. Phan, Adedayo A. Onitilo, Demet G. Yasar, Benjamin C. Powers, Gary C. Doolittle, Gino K. In, Niels Kokot, Geoffrey T. Gibney, Michael B. Atkins, Montaser Shaheen, James A. Warneke, Alexandra Ikeguchi, Jose E. Najera, Bartosz Chmielowski, Joseph G. Crompton, Justin D. Floyd, Eddy Hsueh, Kim A. Margolin, Warren A. Chow, Kenneth F. Grossmann, Eliana Dietrich, Victor G. Prieto, Michael C. Lowe, Elizabeth I. Buchbinder, John M. Kirkwood, Larissa Korde, James Moon, Elad Sharon, Vernon K. Sondak, Antoni Ribas
Summary: This study aimed to investigate whether giving pembrolizumab both before and after surgery would improve event-free survival in patients with resectable stage III or IV melanoma. Results showed that patients who received pembrolizumab both before and after surgery had significantly longer event-free survival. Overall rating: 9 out of 10.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Editorial Material
Oncology
Meghan J. J. Mooradian, Ryan J. J. Sullivan
Summary: The development of effective BRAF-targeted therapy and immune checkpoint inhibition has revolutionized the treatment of advanced metastatic melanoma. However, it remains unclear which treatment option is the best for patients with resected, BRAF-mutant stage III melanoma. This article presents arguments for and against the use of BRAF-targeted therapy and immunotherapy in these patients.
Article
Multidisciplinary Sciences
Rodabe N. Amaria, Michael Postow, Elizabeth M. Burton, Michael T. Tezlaff, Merrick Ross, Carlos Torres-Cabala, Isabella C. Glitza, Fei Duan, Denai R. Milton, Klaus Busam, Lauren Simpson, Jennifer L. McQuade, Michael K. Wong, Jeffrey E. Gershenwald, Jeffrey E. Lee, Ryan P. Goepfert, Emily Z. Keung, Sarah B. Fisher, Allison Betof-Warner, Alexander N. Shoushtari, Margaret Callahan, Daniel Coit, Edmund K. Bartlett, Danielle Bello, Parisa Momtaz, Courtney Nicholas, Aidi Gu, Xuejun Zhang, Brinda Rao Korivi, Madhavi Patnana, Sapna P. Patel, Adi Diab, Anthony Lucci, Victor G. Prieto, Michael A. Davies, James P. Allison, Padmanee Sharma, Jennifer A. Wargo, Charlotte Ariyan, Hussein A. Tawbi
Summary: The combination of Relatlimab and nivolumab improves progression-free survival and has a high pathologic complete response rate in patients with advanced melanoma. This new immunotherapy regimen shows favorable safety compared to other combination immunotherapy regimens.
Review
Oncology
Daniel Thomas, Danielle M. Bello
Summary: Surgical resection is the main treatment for early cutaneous melanoma, but some patients are at risk of relapse, especially those with high-risk features. Immunotherapy targeting checkpoint inhibitors has been shown to improve recurrence-free survival in node-positive melanoma patients.
JOURNAL OF SURGICAL ONCOLOGY
(2021)
Review
Oncology
F. Dimitriou, G. V. Long, A. M. Menzies
Summary: This review discusses the latest clinical trial data, current treatment landscape, and future progress for the management of resected stage IIIB-IIID melanoma. Adjuvant therapy with immunotherapy or targeted therapy is recommended for improving recurrence-free survival in high-risk melanoma patients.
ANNALS OF ONCOLOGY
(2021)
Review
Oncology
Kerianne Boulva, Sameer Apte, Ashley Yu, Alexandre Tran, Risa Shorr, Xinni Song, Michael Ong, Carolyn Nessim
Summary: Contemporary neoadjuvant therapies are safe and effective for high-risk melanoma patients, showing significant rates of pathologic complete response and relapse-free survival, which are considered meaningful surrogate markers for long-term survival.
Article
Surgery
Kristen E. Rhodin, Elizabeth M. Gaughan, Vignesh Raman, April K. Salama, Brent A. Hanks, Riddhishkumar Shah, Douglas S. Tyler, Craig L. Slingluff Jr, Georgia M. Beasley
Summary: This study aimed to evaluate the feasibility and impact of neoadjuvant therapy (NT) in patients with advanced melanoma amenable to surgical resection. Prospective data from 3 institutions showed that NT could potentially be effective in patients with advanced melanoma eligible for surgery.
Article
Urology & Nephrology
Alberto Martini, Giuseppe Fallara, Francesco Pellegrino, Giuseppe Ottone Cirulli, Alessandro Larcher, Andrea Necchi, Francesco Montorsi, Umberto Capitanio
Summary: The treatment landscape for renal cell carcinoma is rapidly evolving, with nine studies currently evaluating the role of immunotherapy in the neoadjuvant setting and four studies in the adjuvant setting.
WORLD JOURNAL OF UROLOGY
(2021)
Review
Oncology
Omar Bushara, Jerica Tidwell, James R. Wester, John Miura
Summary: The current standard of care for locally advanced melanoma is surgery followed by systemic therapy, but there is growing evidence supporting the use of neoadjuvant therapy. Neoadjuvant therapy has been shown to downstage tumors, improve outcomes, and allow for prognostication based on the initial response to treatment. This article aims to review clinical trials of neoadjuvant therapy in locally advanced melanoma.
Article
Oncology
Judith M. Versluis, Irene L. M. Reijers, Elisa A. Rozeman, Alexander M. Menzies, Alexander C. J. van Akkooi, Michel W. Wouters, Sydney Ch'ng, Robyn P. M. Saw, Richard A. Scolyer, Bart A. van de Wiel, Bastian Schilling, Georgina Long, Christian U. Blank
Summary: Research shows that neoadjuvant ipilimumab plus nivolumab treatment induces similar pathological responses in primary site melanoma lesions or in-transit metastases as in lymph node metastases, indicating that upfront surgery may not be necessary for these melanoma lesions prior to neoadjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Chemistry, Multidisciplinary
Fengyun Shen, Lele Sun, Lihua Wang, Rui Peng, Chunhai Fan, Zhuang Liu
Summary: This study reported a novel immune adjuvant that can transdermally deliver chemotherapy drugs into melanoma, induce immunogenic death of tumor cells, and trigger systemic tumor-specific immune responses.
Review
Oncology
Iyad Kobeissi, Ahmad A. Tarhini
Summary: The incidence of cutaneous melanoma continues to increase, posing a significant mortality risk. Surgical excision is often curative, but patients with resected stages IIB-IV are at high risk for relapse and death, requiring systemic adjuvant therapy. High-dose interferon-alpha, previously used, improved relapse-free survival and overall survival, but is no longer in use. Adjuvant therapy with ipilimumab at 10 mg/kg showed significant improvements in relapse-free survival and overall survival, but at a high cost in terms of toxicity. Nivolumab, pembrolizumab, and BRAF-MEK inhibitors have shown significant improvements in relapse-free survival compared to ipilimumab, leading to changes in adjuvant therapy for resected stages III-IV melanoma.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)
Review
Oncology
Mariam Saad, Ahmad A. Tarhini
Summary: This review provides an overview of neoadjuvant immunotherapy and targeted therapy for locoregionally advanced melanoma. Recent studies have shown significant advancements in reducing the risk of relapse and improving overall survival through immune checkpoint inhibitors and targeted therapy. Neoadjuvant pembrolizumab has demonstrated better event-free survival compared to standard surgery and adjuvant therapy.
CURRENT ONCOLOGY REPORTS
(2023)
Review
Oncology
Anna S. Koerner, Ryan H. Moy, Sandra W. Ryeom, Sam S. Yoon
Summary: Gastric cancer is a common and deadly disease worldwide. Many patients are diagnosed with unresectable advanced disease due to the ambiguous symptoms. However, some patients have locally advanced gastric cancer (LAGC), which can be treated with surgical resection and perioperative chemotherapy. The optimal treatment for LAGC varies for different subtypes, but promising treatments based on molecular subtypes and biomarkers of LAGC are on the horizon.
Review
Oncology
Ankit Patel, Joseph Skitzki
Summary: Adjuvant systemic therapy for cutaneous melanoma has undergone practice-changing shifts, with the success of immunotherapies and targeted therapies in the metastatic setting leading to investigations in the adjuvant and neoadjuvant setting, potentially improving clinical outcomes for high-risk resected melanoma patients.
JOURNAL OF SURGICAL ONCOLOGY
(2022)
Review
Oncology
Albrecht Stenzinger, Arndt Vogel, Ulrich Lehmann, Angela Lamarca, Paul Hofman, Luigi Terracciano, Nicola Normanno
Summary: Cholangiocarcinomas are a heterogeneous group of tumors with distinct genomic alterations. Next-generation sequencing is a powerful tool for identifying gene variants and guiding personalized treatment for patients with cholangiocarcinomas. Understanding the use of NGS in molecular profiling is crucial for healthcare professionals to optimize treatment outcomes.
CANCER TREATMENT REVIEWS
(2024)